|
|
|
|
THE EXPANDING LATAM CANNABIS MARKET AND THE TWO PLAYERS BEST POSITIONED TO WIN |
||||
|
Home to 650 million+ people across 33 countries, the Latin America and Caribbean (LAC) region is experiencing a burgeoning cannabis market, thanks to a favorable growing environment, low production cost, and increasing foreign direct investments (FDI). LAC is blessed with fertile soil, abundant water, and warm weather, allowing the regional cannabis farmers to grow high-quality marijuana during the growing season, which is nearly year-round. The region also benefits from low-cost labor, with overall production cost 80%-90% lower than in North America. In Colombia, for example, cultivating a gram of dried flower for medicinal grade cannabis costs about 6 cents, compared to $1.25 per gram in North America. These two factors have garnered significant attention from cannabis companies across North and South America, including operators like Canopy Growth (CGC), Khiron Life Sciences (KHRNF), Aurora Cannabis (ACB), and Clever Leaves (CLVR). This is also evident in the large FDI that flew into the LAC’s top 5 economies in 2019: $72.0 billion in Brazil, $32.9 billion in Mexico, $14.5 billion in Colombia, $11.4 billion in Chile, and $8.9 billion in Peru. Given the combination of these factors, LAC’s legal cannabis market – which stood at $172 million in 2020 – and is estimated to grow to $253 million this year and ~$830 million by 2024, according to Prohibition Partners.
Source: Intro-act, Prohibition Partners, Statista Mexico, Brazil, and Colombia are the three leading nations where growth of legal cannabis will outpace that of other Latin American economies. We discuss the current regulatory environment and the market size of these three countries below. - Mexico. Globally known for illegal marijuana cultivation during the 1980s, Mexico legalized medical marijuana in 2017; however, the regulatory structure for medical cannabis came this year in January. The long-awaited regulation will allow businesses to start applying for research licenses to bring medical marijuana products to market. More importantly, in late June, the Mexican Supreme Court voted to decriminalize private cultivation and consumption of recreational marijuana. This watershed court decision will add fresh momentum to the sweeping legalization bill, backed by President Andrés Manuel López Obrador, which has stalled for approval in the Mexican Senate since March. If approved, the bill will make Mexico one of the world's largest legal markets, generating ~$350 million in legal cannabis sales by 2024. - Brazil. Except for medical use, the sale and purchase of cannabis for recreational purposes is still illegal in the largest LatAm country. Even with a restrictive market, however, Brazil’s medical cannabis program has been a success thus far with an estimated 14,500+ prescriptions in 2020, up 530% from 2018. Moreover, the number of medical patients crossed over 2,500 in the first two months of 2021, up from 2,054 and 318 patients in the same period during 2021 and 2018. In June, a bill authorizing the cultivation and sale of medical-use cannabis by licensed sellers passed through Brazil’s lower house of Congress. However, the bill will face a roadblock from President Jair Bolsonaro’s cabinet given his opposing stance on cannabis. While the prospects of full cannabis legalization remain unclear, Brazil could see a ~$150 million cannabis market by 2024 once marijuana is legalized. - Colombia. Colombia decriminalized marijuana in 2012 and legalized medical marijuana in 2015, allowing for commercial cultivation, processing, and export of medical cannabis products excluding flower. On July 23, however, the ban on exporting dried cannabis flower was lifted with President Ivan Duque signing a decree, providing a further boost to the country’s marijuana industry, which exports to various international markets like the U.S., UK, Germany, and Israel, in addition to serving over 3,000 domestic patients. According to Prohibition Partners, Colombia’s legal cannabis market could reach over $100+ million in 2024.
Source: Intro-act, Prohibition Partners We believe KHRNF and CLVR are in a prime position to emerge as the leading cannabis operators in the LAC region. - Khiron is a vertically integrated medical cannabis player with core operations in LatAm (Colombia and Peru) and Europe (Germany and the UK). It was the first company to sell legal medical cannabis (CBD and THC) in Colombia and Peru in 2020, and is planning to commence sales in Brazil and Mexico in 2021. It has a cultivation area of 80,000 sq. ft. with up to 20 hectares available for expansion in Colombia and a production capacity of 9 tons of dry flower and extraction up to 3 tons of full-spectrum extract. Through its wholly owned medical health centers and unique telemedicine platforms, Khiron combines a patient-centered strategy, physician education programs, scientific competence, product innovation, and agricultural infrastructure to generate prescriptions and brand loyalty with patients globally. This strategy has allowed Khiron to serve 10,000+ medical cannabis patients in Colombia to date with over 18,000 prescriptions in 1H21 across nine clinics and health centers. Moreover, Khiron’s 1Q21 sales grew 49% y/y to $2.8 million, with medical cannabis sales contributing 20% and international sales representing ~10% of the total medical cannabis product revenues. At the same time, its gross margins also improved remarkably from 16% in 4Q20 to 38% and as of 1Q21 it had $12.5 million in cash. Overall, Khiron’s proven Colombian business model, combined with its expanding presence in global markets, makes it one of the attractive LatAm plays. - Clever Leaves is a multinational cannabis operator (MNO) with operations and investments in the U.S., Canada, Colombia, Germany, and Portugal. The company stands out because of its scale – it has a cultivation capacity of 1.9 million sq. ft. – nearly ~50% of Colombia’s national and ~18% of the global THC quota. To further boost its presence in the LatAm region, the company announced an agreement with Verdemed to supply finished CBD products for the Brazilian and Peruvian markets in April 2021. It has been granted the Good Agricultural and Collecting Practices (GACP) Certification for quality and consistency in the cultivation and harvest of medical cannabis, and holds EU GMP certification for its Colombia operations. It has also emerged as one of the leading low-cost medical marijuana cultivations, with a production cost of <$0.20/gram, much lower than its Canadian counterparts which costs an average of $2.07/gram. Given its scale and ability to maintain cost advantage, Clever Leaves delivered a best-in-class performance during 1Q21, with sales growing 19% y/y to $3.5 million and gross margin of 64%. CLVR is on track to finish 2021 with $20 million in revenue and a gross margin of ~61% as the company seeks worldwide business growth opportunities and enters new markets. - In addition to the above two players, other names with a LAC presence include PharmaCielo (PCLOF), Tilray (TLRY), and CGC. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CANNA EVENTS CALENDAR
|
Chart 33: Cannabis Company Events Calendar – Upcoming Conference Calls |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source: Intro-act, New Cannabis Ventures
|
Chart 34: Cannabis Company Events Calendar – Recent Conference Calls |
||||||||||||||||||||||||||||||||||||||||||||||||
|
Source: Intro-act, New Cannabis Ventures
|
Chart 35: Cannabis IPO Pipeline |
|||||||||||||||||||||||||||||||||||||||||||||
|
Source: Intro-act, New Cannabis Ventures
|
Chart 36: Cannabis SPAC Pipeline |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source: Intro-act, New Cannabis Ventures
|
Chart 37: Cannabis Industry Events Calendar |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source: Intro-act, Cannabis Business Times
CANNA INDEX
|
Chart 38: U.S. Cannabis Index |
|
|
Source: Intro-act, The Marijuana Index
|
Chart 39: Canada Cannabis Index |
|
|
Source: Intro-act, The Marijuana Index
COMPARABLES & COMPANY PROFILE LINKS
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
8/3/2021 |
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
|
Peer Set |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Canadian LP - Cultivation, Processing (and Dispensing) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
1 |
CGC |
18.47 |
7,263 |
6,882 |
206% |
-25% |
-25% |
430 |
607 |
11.3 x |
(269) |
(120) |
- |
7.24 |
2.6 x |
||
|
2 |
TLRY |
14.08 |
6,325 |
6,781 |
376% |
-69% |
70% |
210 |
776 |
8.7 x |
(33) |
61 |
111.0 x |
9.99 |
1.4 x |
||
|
3 |
CRON |
7.31 |
2,715 |
1,483 |
117% |
-33% |
5% |
51 |
84 |
17.6 x |
(148) |
(120) |
- |
4.23 |
1.7 x |
||
|
4 |
HRVSF |
3.67 |
940 |
1,787 |
23% |
-74% |
70% |
276 |
430 |
4.2 x |
51 |
120 |
14.9 x |
0.90 |
4.1 x |
||
|
5 |
ACB |
7.00 |
1,386 |
1,350 |
171% |
-47% |
-16% |
205 |
218 |
6.2 x |
(103) |
(26) |
- |
8.75 |
0.8 x |
||
|
6 |
OGI |
2.57 |
768 |
610 |
151% |
-61% |
93% |
59 |
86 |
7.1 x |
(22) |
(21) |
- |
1.39 |
1.8 x |
||
|
7 |
TRSSF |
8.48 |
1,518 |
608 |
92% |
-64% |
105% |
180 |
352 |
1.7 x |
65 |
155 |
3.9 x |
1.10 |
7.7 x |
||
|
8 |
HEXO |
3.85 |
587 |
545 |
187% |
-40% |
5% |
88 |
171 |
3.2 x |
(12) |
(0) |
- |
3.48 |
1.1 x |
||
|
9 |
SNDL |
0.80 |
1,587 |
164 |
397% |
-83% |
202% |
44 |
43 |
3.9 x |
(8) |
5 |
31.1 x |
0.47 |
1.7 x |
||
|
10 |
CBWTF |
0.20 |
166 |
246 |
105% |
-60% |
3% |
51 |
89 |
2.8 x |
(28) |
(10) |
- |
0.22 |
0.9 x |
||
|
11 |
GDNSF |
1.56 |
120 |
201 |
147% |
-67% |
5% |
48 |
89 |
2.3 x |
(4) |
11 |
18.0 x |
0.48 |
3.2 x |
||
|
12 |
FLWPF |
0.14 |
52 |
90 |
283% |
-7% |
-44% |
11 |
|
|
(16) |
|
|
0.21 |
0.7 x |
||
|
13 |
CNTMF |
0.85 |
157 |
229 |
60% |
-82% |
10% |
57 |
109 |
2.1 x |
13 |
39 |
5.8 x |
0.23 |
3.7 x |
||
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
|
14 |
TGODF |
0.26 |
136 |
123 |
105% |
-39% |
96% |
28 |
|
|
(26) |
|
|
0.25 |
1.0 x |
||
|
15 |
FLGC |
10.14 |
426 |
411 |
1% |
-72% |
|
|
14 |
28.7 x |
|
3 |
137.0 x |
0.19 |
54.4 x |
||
|
16 |
ALEAF |
0.29 |
96 |
111 |
268% |
-9% |
-22% |
37 |
78 |
1.4 x |
|
(0) |
- |
0.40 |
0.7 x |
||
|
17 |
ROMJF |
1.94 |
108 |
99 |
75% |
-8% |
-31% |
13 |
27 |
3.7 x |
(12) |
(3) |
- |
0.66 |
2.9 x |
||
|
18 |
WDDMF |
0.20 |
50 |
94 |
392% |
-17% |
6% |
28 |
|
|
(48) |
|
|
0.27 |
0.8 x |
||
|
19 |
48NORTH CANNABIS CORP. |
NCNNF |
0.10 |
22 |
25 |
270% |
-64% |
-18% |
|
|
|
|
|
|
0.12 |
0.8 x |
|
|
20 |
VVCIF |
0.09 |
34 |
24 |
257% |
-6% |
-13% |
29 |
|
|
|
|
|
0.33 |
0.3 x |
||
|
21 |
REZN-CA |
0.03 |
8 |
6 |
195% |
-16% |
|
|
|
|
|
|
|
0.01 |
3.4 x |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US - Cultivation, Processing (and Dispensing) - MSO & SSO |
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
22 |
CURLF |
12.06 |
7,343 |
8,788 |
52% |
-52% |
1% |
790 |
1,465 |
6.0 x |
187 |
447 |
19.6 x |
2.34 |
5.2 x |
||
|
23 |
GTBIF |
30.94 |
5,818 |
6,857 |
26% |
-63% |
26% |
648 |
939 |
7.3 x |
225 |
346 |
19.8 x |
5.02 |
6.2 x |
||
|
24 |
VRNOF |
15.49 |
2,031 |
4,648 |
81% |
-11% |
|
|
1,004 |
4.6 x |
|
435 |
10.7 x |
5.35 |
2.9 x |
||
|
25 |
CRLBF |
10.95 |
2,597 |
3,118 |
60% |
-51% |
11% |
588 |
936 |
3.3 x |
129 |
260 |
12.0 x |
3.05 |
3.6 x |
||
|
26 |
TCNNF |
33.05 |
2,301 |
4,181 |
63% |
-51% |
5% |
619 |
951 |
4.4 x |
295 |
426 |
9.8 x |
4.04 |
8.2 x |
||
|
27 |
CCHWF |
4.80 |
1,518 |
1,351 |
64% |
-40% |
-3% |
261 |
603 |
2.2 x |
17 |
132 |
10.3 x |
1.58 |
3.0 x |
||
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
|
28 |
MRCWF-OTC |
1.75 |
0 |
|
128% |
-60% |
|
|
|
|
|
|
|
|
|
||
|
29 |
AYRWF |
29.36 |
1,435 |
889 |
28% |
-71% |
236% |
180 |
478 |
1.9 x |
66 |
166 |
5.3 x |
16.13 |
1.8 x |
||
|
30 |
VFF |
9.27 |
753 |
687 |
119% |
-54% |
-9% |
209 |
263 |
2.6 x |
8 |
17 |
40.2 x |
4.27 |
2.2 x |
||
|
31 |
ACRHF |
3.24 |
238 |
410 |
178% |
-41% |
5% |
|
|
|
|
|
|
3.29 |
1.0 x |
||
|
32 |
RWBYF |
0.80 |
154 |
284 |
105% |
-59% |
34% |
69 |
255 |
1.1 x |
|
50 |
5.6 x |
0.65 |
1.2 x |
||
|
33 |
AWWH |
11.05 |
1,886 |
2,243 |
43% |
-16% |
|
|
405 |
5.5 x |
|
115 |
19.4 x |
(0.09) |
-129.9 x |
||
|
34 |
MRMD |
0.86 |
282 |
331 |
40% |
-85% |
83% |
|
|
|
|
|
|
0.05 |
18.2 x |
||
|
35 |
GRAMF |
4.15 |
403 |
403 |
236% |
-5% |
-59% |
|
275 |
1.5 x |
|
(11) |
- |
0.18 |
23.6 x |
||
|
36 |
GAEGF |
1.90 |
262 |
219 |
58% |
-5% |
|
|
226 |
1.0 x |
|
44 |
5.0 x |
0.85 |
2.2 x |
||
|
37 |
FFNTF |
1.14 |
671 |
245 |
74% |
-56% |
485% |
123 |
230 |
1.1 x |
19 |
72 |
3.4 x |
0.07 |
15.2 x |
||
|
38 |
ITHUF |
0.17 |
29 |
229 |
204% |
-72% |
-14% |
173 |
|
|
|
|
|
0.17 |
1.0 x |
||
|
39 |
FLOOF |
0.15 |
47 |
154 |
153% |
-46% |
-4% |
49 |
112 |
1.4 x |
(28) |
22 |
7.1 x |
(0.04) |
-3.8 x |
||
|
40 |
DBCCF |
0.28 |
96 |
131 |
8% |
-83% |
441% |
38 |
59 |
2.2 x |
|
10 |
13.8 x |
0.08 |
3.3 x |
||
|
41 |
HSTRF |
0.20 |
48 |
45 |
106% |
-72% |
2% |
|
|
|
|
|
|
0.05 |
4.3 x |
||
|
42 |
TRTC |
0.26 |
61 |
50 |
212% |
-77% |
75% |
|
|
|
|
|
|
0.25 |
1.0 x |
||
|
43 |
BMMJ |
0.33 |
36 |
38 |
200% |
-52% |
-15% |
|
|
|
|
|
|
0.30 |
1.1 x |
||
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
|
Medical Cannabis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
44 |
JAZZ |
169.53 |
10,337 |
10,156 |
11% |
-37% |
3% |
2,436 |
3,374 |
3.0 x |
1,159 |
|
|
66.77 |
2.5 x |
||
|
45 |
ARNA |
59.98 |
3,638 |
2,594 |
50% |
-1% |
-22% |
0 |
2 |
1,173.3 x |
|
|
|
17.92 |
3.3 x |
||
|
46 |
CARA |
11.64 |
583 |
416 |
155% |
-1% |
-23% |
129 |
43 |
9.7 x |
12 |
|
|
4.61 |
2.5 x |
||
|
47 |
IHL-ASX |
0.18 |
190 |
180 |
47% |
-79% |
48% |
|
|
|
|
|
|
0.01 |
21.3 x |
||
|
48 |
SOLCF |
2.60 |
139 |
179 |
117% |
-90% |
27% |
|
|
|
|
|
|
7.43 |
0.3 x |
||
|
49 |
COPHF |
0.09 |
111 |
109 |
975% |
-97% |
-42% |
|
|
|
|
|
|
0.01 |
8.0 x |
||
|
50 |
CRBP |
1.36 |
169 |
71 |
622% |
-33% |
8% |
3 |
|
|
|
|
|
0.73 |
1.9 x |
||
|
51 |
MJNA |
0.03 |
118 |
121 |
623% |
-58% |
72% |
|
|
|
|
|
|
0.02 |
1.4 x |
||
|
52 |
DOCRF |
1.48 |
299 |
103 |
76% |
-69% |
36% |
17 |
104 |
1.0 x |
(5) |
4 |
27.2 x |
0.70 |
2.1 x |
||
|
53 |
XPHYF |
1.47 |
100 |
69 |
112% |
-32% |
42% |
|
|
|
|
|
|
0.06 |
23.4 x |
||
|
54 |
CRTPF |
2.21 |
90 |
43 |
90% |
-33% |
60% |
0 |
1 |
42.9 x |
|
|
|
0.40 |
5.6 x |
||
|
55 |
EMD-ASX |
0.13 |
32 |
28 |
67% |
-76% |
77% |
|
|
|
|
|
|
0.02 |
7.5 x |
||
|
56 |
AQSZF |
0.10 |
13 |
12 |
130% |
-41% |
16% |
|
|
|
|
|
|
0.01 |
7.8 x |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
|
CBD/Hemp |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
57 |
CWBHF |
3.16 |
346 |
438 |
122% |
-34% |
-4% |
97 |
127 |
3.5 x |
(21) |
(2) |
- |
1.73 |
1.8 x |
||
|
58 |
YCBD |
2.44 |
138 |
121 |
180% |
-28% |
-17% |
46 |
55 |
2.2 x |
(7) |
(3) |
- |
1.52 |
1.6 x |
||
|
59 |
EPWCF |
0.37 |
124 |
119 |
434% |
-95% |
68% |
|
|
|
|
|
|
(0.00) |
-183.8 x |
||
|
60 |
BTTR |
3.99 |
118 |
71 |
171% |
-64% |
41% |
|
54 |
1.3 x |
|
(3) |
- |
(3.00) |
-1.3 x |
||
|
61 |
CVSI |
0.31 |
33 |
35 |
260% |
-8% |
-34% |
21 |
23 |
1.5 x |
(10) |
(9) |
- |
0.11 |
2.8 x |
||
|
62 |
CBDHF |
0.26 |
36 |
14 |
1318% |
-4% |
|
|
|
|
|
|
|
0.17 |
1.5 x |
||
|
Downstream - Distribution/Brand/Marketing/Retail/Delivery |
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
63 |
PLNHF |
5.22 |
1,025 |
1,196 |
66% |
-50% |
-7% |
78 |
163 |
7.3 x |
11 |
48 |
24.8 x |
0.94 |
5.6 x |
||
|
64 |
TPB |
52.09 |
986 |
1,281 |
17% |
-50% |
17% |
440 |
467 |
2.7 x |
108 |
111 |
11.5 x |
6.89 |
7.6 x |
||
|
65 |
JUSHF |
4.85 |
731 |
687 |
87% |
-65% |
-17% |
114 |
272 |
2.5 x |
6 |
58 |
11.8 x |
0.50 |
9.7 x |
||
|
66 |
LQSIF |
5.19 |
208 |
371 |
29% |
-48% |
11% |
751 |
780 |
0.5 x |
58 |
42 |
8.8 x |
3.97 |
1.3 x |
||
|
67 |
HITI |
6.48 |
308 |
331 |
105% |
-76% |
116% |
125 |
|
|
17 |
|
|
1.86 |
3.5 x |
||
|
68 |
NBEV |
1.91 |
260 |
258 |
139% |
-20% |
-28% |
341 |
530 |
0.5 x |
(7) |
36 |
7.1 x |
1.25 |
1.5 x |
||
|
69 |
FFLWF |
0.75 |
248 |
168 |
61% |
-29% |
72% |
149 |
224 |
0.8 x |
5 |
16 |
10.7 x |
0.21 |
3.5 x |
||
|
70 |
MMNFF |
0.24 |
170 |
155 |
504% |
-57% |
138% |
129 |
151 |
1.0 x |
(174) |
(8) |
- |
0.34 |
0.7 x |
||
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
|
71 |
GNLN |
3.35 |
57 |
104 |
161% |
-45% |
-16% |
138 |
160 |
0.6 x |
(23) |
(6) |
- |
1.15 |
2.9 x |
||
|
72 |
SLGWF |
0.18 |
62 |
70 |
233% |
-54% |
-30% |
32 |
|
|
(4) |
|
|
0.14 |
1.3 x |
||
|
73 |
DLTNF |
0.33 |
34 |
60 |
79% |
-13% |
-19% |
54 |
|
|
|
|
|
0.22 |
1.5 x |
||
|
74 |
CHALF |
0.76 |
29 |
27 |
167% |
-93% |
52% |
|
|
|
|
|
|
0.24 |
3.2 x |
||
|
Extraction, Genetics, Canna Science, etc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
75 |
XXII |
3.10 |
503 |
473 |
96% |
-82% |
41% |
28 |
41 |
11.5 x |
|
|
|
0.34 |
9.0 x |
||
|
76 |
VLNCF |
2.04 |
379 |
377 |
62% |
-49% |
57% |
73 |
152 |
2.5 x |
(11) |
|
|
0.88 |
2.3 x |
||
|
77 |
NEPT |
0.78 |
130 |
107 |
363% |
-6% |
-50% |
46 |
50 |
2.1 x |
(44) |
(31) |
- |
0.70 |
1.1 x |
||
|
78 |
HCANF |
0.04 |
85 |
95 |
299% |
-51% |
7% |
27 |
|
|
|
|
|
0.05 |
0.8 x |
||
|
79 |
CNVCF |
0.30 |
130 |
129 |
545% |
-83% |
67% |
|
|
|
|
|
|
(0.01) |
-46.3 x |
||
|
80 |
NWVCF |
0.79 |
88 |
78 |
86% |
-26% |
-12% |
29 |
32 |
2.4 x |
(4) |
(1) |
- |
0.18 |
4.5 x |
||
|
81 |
CANSF |
0.71 |
88 |
51 |
147% |
-48% |
-20% |
0 |
|
|
|
|
|
0.15 |
4.8 x |
||
|
82 |
APDN |
5.34 |
40 |
26 |
155% |
-7% |
5% |
5 |
18 |
1.5 x |
|
|
|
2.49 |
2.1 x |
||
|
83 |
MEDIF |
0.34 |
87 |
22 |
170% |
-5% |
37% |
30 |
46 |
0.5 x |
(24) |
(11) |
- |
0.37 |
0.9 x |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
|
Input Materials - Nutrients, Hydroponic Equipment, etc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
84 |
SMG |
175.98 |
9,803 |
12,539 |
45% |
-19% |
-12% |
4,960 |
4,581 |
2.7 x |
952 |
796 |
15.8 x |
16.89 |
10.4 x |
||
|
85 |
HYFM |
49.71 |
2,183 |
2,501 |
92% |
-16% |
-5% |
|
531 |
4.7 x |
|
52 |
48.5 x |
(4.36) |
-11.4 x |
||
|
86 |
GRWG |
40.13 |
2,361 |
1,847 |
69% |
-80% |
20% |
250 |
511 |
3.6 x |
28 |
63 |
29.3 x |
5.99 |
6.7 x |
||
|
87 |
MBII |
1.27 |
222 |
238 |
129% |
-16% |
1% |
40 |
53 |
4.5 x |
(9) |
(4) |
- |
0.20 |
6.3 x |
||
|
Testing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
88 |
PMD |
7.31 |
40 |
47 |
14% |
-51% |
44% |
|
|
|
|
|
|
2.31 |
3.2 x |
||
|
89 |
EVIO |
0.00 |
1 |
14 |
2400% |
-8% |
-48% |
|
|
|
|
|
|
(0.16) |
0.0 x |
||
|
90 |
FLURF |
0.15 |
18 |
6 |
370% |
-61% |
292% |
|
|
|
|
|
|
0.03 |
4.9 x |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Technology, Ancillary Products and Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
91 |
MAPS |
13.18 |
840 |
1,703 |
124% |
-24% |
3% |
|
|
|
|
|
|
0.46 |
28.4 x |
||
|
92 |
KSHB |
0.86 |
137 |
145 |
145% |
-50% |
7% |
114 |
153 |
0.9 x |
(0) |
6 |
24.7 x |
0.75 |
1.1 x |
||
|
93 |
NEXCF |
1.59 |
129 |
63 |
339% |
-6% |
-43% |
18 |
|
|
|
|
|
0.18 |
8.9 x |
||
|
94 |
SLHG |
3.39 |
129 |
120 |
122% |
-88% |
-26% |
15 |
77 |
1.6 x |
(3) |
7 |
17.4 x |
0.62 |
5.5 x |
||
|
95 |
KERN |
3.41 |
86 |
104 |
206% |
-36% |
5% |
13 |
21 |
5.0 x |
(14) |
(8) |
- |
2.04 |
1.7 x |
||
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
|
96 |
FORA |
10.92 |
355 |
355 |
312% |
-15% |
|
|
|
|
|
|
|
0.90 |
12.2 x |
||
|
97 |
BLOZF |
0.80 |
89 |
83 |
144% |
-66% |
15% |
|
|
|
|
|
|
0.06 |
14.3 x |
||
|
98 |
VEXTF |
0.60 |
41 |
71 |
118% |
-65% |
-22% |
|
|
|
|
|
|
0.40 |
1.5 x |
||
|
99 |
AUSAF |
0.20 |
34 |
29 |
209% |
-59% |
47% |
|
|
|
|
|
|
0.13 |
1.5 x |
||
|
100 |
AGFY |
18.38 |
373 |
237 |
21% |
-63% |
|
|
59 |
4.0 x |
|
(11) |
- |
7.19 |
2.6 x |
||
|
101 |
UGRO |
9.50 |
103 |
103 |
1606% |
-96% |
265% |
|
|
|
|
|
|
|
|
||
|
Real Estate & Investors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
102 |
IIPR |
211.94 |
5,071 |
4,562 |
5% |
-52% |
16% |
139 |
210 |
21.7 x |
119 |
193 |
23.6 x |
62.84 |
3.4 x |
||
|
103 |
CODI |
24.78 |
1,608 |
3,042 |
10% |
-37% |
27% |
1,843 |
1,922 |
1.6 x |
336 |
342 |
8.9 x |
11.37 |
2.2 x |
||
|
104 |
AFCG |
20.74 |
340 |
213 |
21% |
-5% |
|
|
45 |
4.8 x |
|
|
|
16.18 |
1.3 x |
||
|
105 |
POWER REIT |
PW |
36.81 |
122 |
117 |
41% |
-54% |
38% |
|
12 |
10.1 x |
|
|
|
14.95 |
2.5 x |
|
|
106 |
CNPOF |
1.41 |
201 |
99 |
107% |
-65% |
53% |
8 |
4 |
27.5 x |
(9) |
(4) |
- |
1.74 |
0.8 x |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
|
SPACs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
107 |
SPKC.UT.USD-NEOL |
|
|
|
|
|
|
|
|
|
|
|
|
0.00 |
|
||
|
108 |
SPKBU-USA |
9.91 |
285 |
355 |
5% |
-2% |
|
|
|
|
|
|
|
7.44 |
1.3 x |
||
|
109 |
GNRSU |
10.41 |
228 |
228 |
38% |
-5% |
-5% |
|
|
|
|
|
|
|
|
||
|
110 |
TUSCAN HOLDINGS CORP. II |
THCAU |
10.73 |
236 |
236 |
67% |
-14% |
-16% |
|
|
|
|
|
|
|
|
|
|
111 |
TCACU |
9.98 |
200 |
200 |
10% |
-3% |
|
|
|
|
|
|
|
|
|
||
|
112 |
CHOICE CONSOLIDATION CORP |
CDXXF-USA |
9.98 |
172 |
214 |
20% |
-20% |
|
|
|
|
|
|
|
(0.34) |
-29.4 x |
|
|
113 |
MCMJ |
9.95 |
163 |
163 |
13% |
-3% |
-2% |
|
|
|
|
|
|
7.69 |
1.3 x |
||
|
114 |
ACKIU |
10.24 |
141 |
141 |
7% |
-2% |
0% |
|
|
|
|
|
|
|
|
||
|
115 |
CERAF |
10.00 |
120 |
271 |
50% |
-10% |
|
|
|
|
|
|
|
(0.37) |
-27.3 x |
||
|
116 |
BGPPF |
9.70 |
112 |
33 |
931% |
-100% |
|
|
|
|
|
|
|
3.43 |
2.8 x |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
Mkt Cap (Mns) |
Ent Val (Mns) |
Price Performance |
Sales |
EBITDA |
Book Value |
||||||||
|
|
|
|
% to High |
% to Low |
% YTD |
LTM |
NTM |
EV/Sales |
LTM |
NTM |
EV/ EBITDA |
Book/ Share |
P/ |
||||
|
Diversified |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
117 |
MO |
47.80 |
88,145 |
114,547 |
10% |
-25% |
17% |
21,227 |
21,446 |
5.3 x |
11,887 |
12,421 |
9.2 x |
1.77 |
27.1 x |
||
|
118 |
STZ |
221.66 |
37,295 |
52,326 |
10% |
-28% |
1% |
8,678 |
8,677 |
6.0 x |
3,210 |
3,282 |
15.9 x |
64.49 |
3.4 x |
||
|
119 |
INCR-TAE |
6.58 |
281 |
276 |
41% |
-43% |
29% |
|
|
|
|
|
|
3.22 |
2.0 x |
||
|
120 |
CLVR |
9.86 |
246 |
246 |
97% |
-19% |
11% |
|
22 |
11.4 x |
|
(25) |
- |
3.30 |
3.0 x |
||
|
121 |
TLLTF |
0.47 |
153 |
250 |
60% |
-54% |
62% |
168 |
228 |
1.1 x |
15 |
37 |
6.8 x |
0.77 |
0.6 x |
||
|
122 |
SHWZ |
2.30 |
97 |
133 |
41% |
-54% |
54% |
40 |
|
|
|
|
|
2.58 |
0.9 x |
||
|
123 |
PCLOF |
1.19 |
175 |
117 |
96% |
-76% |
10% |
3 |
21 |
5.4 x |
(17) |
(2) |
- |
0.11 |
10.5 x |
||
|
124 |
LOWLF |
1.21 |
85 |
125 |
78% |
-31% |
6% |
57 |
106 |
1.2 x |
(12) |
22 |
5.8 x |
0.72 |
1.7 x |
||
|
125 |
KHRNF |
0.25 |
38 |
20 |
147% |
-17% |
14% |
9 |
27 |
0.7 x |
(17) |
(12) |
- |
0.29 |
0.9 x |
||
Important Disclosures
Analyst Certification: I, Peter Wright, certify that the views expressed in the research report accurately reflect my personal views about the subject securities or issues. I also do not receive direct or indirect compensation based on my recommendations or views. Intro-act, Inc. (Intro-act) issued this report and may seek fees for the assistance with investor targeting, access, and further investor preparation services. Intro-act, Inc. will not seek renumeration for any investment banking service or investment advice.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources who are believed to be reliable. However, the issuer and related parties, as well as Intro-act, do not guarantee the accuracy or completeness of this report, and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Intro-act analysts at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, and estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Intro-act, Inc. shall not be liable for any direct, indirect, or consequential losses, loss of profits, damages, or costs or expenses incurred or suffered by you arising out or in connection with the access to, use of, or reliance on any information contained in this note.
No personalized advice: The information that we provide should not be construed in any manner whatsoever as personalized advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Intro-act’s solicitation to affect, or attempt to affect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.
Investment in securities mentioned: Intro-act has a restrictive policy relating to personal dealing and conflicts of interest. Intro-act, Inc. does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees, and contractors of Intro-act may have a position in any or related securities mentioned in this report, subject to Intro-act’s policies on personal dealing and conflicts of interest.
Copyright: Copyright 2021 Intro-act, Inc. (Intro-act).
Intro-act is not registered as an investment adviser with the Securities and Exchange Commission. Intro-act relies upon the “publishers’ exclusion” from the definition of investment adviser under Section 202(a) (11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Intro-act does not offer or provide personal advice, and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell, or hold that or any security, or that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person.